Completed PHASE2 INTERVENTIONAL NCT00317421

Effect of Regular Sildenafil on Blood Pressure and Arterial Function in Hypertension

Effects of Regular Treatment With Sildenafil on Blood Pressure and Endothelial Function in Untreated Hypertensives

Sponsor: Pfizer

Updated 4 times since 2017 Last updated: Apr 20, 2006 Started: Mar 31, 2004 Completion: Nov 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Hypertension and is currently completed. Pfizer leads this study, which shows 4 recorded versions since 2004 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2017 — Jan 2021 [monthly]

Completed PHASE2

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer
University of Edinburgh

Data source: University of Edinburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Edinburgh, United Kingdom